EWTX Edgewise Therapeutics, Inc.
EWTX Edgewise Therapeutics, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-08-17 1 bull converging
POC $15.06 · VWAP $28.75 · +53.2% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
EWTX Price Structure
Loading timeframes…
Peers
Every watchlist EWTX belongs to, members best 30-day change first — EWTX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-03-31: diluted EPS $-0.46, net income $-49M (SEC filing). Across the print the stock moved -4.5% (close before → first close after).
full note →Against street estimates
How EWTX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about EWTX from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21
- Edgewise Therapeutics (EWTX) Stock Price, News & Analysis
- Edgewise Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Progress Continues
- Edgewise Therapeutics Inc. (EWTX) Q1 2026 Earnings
- Edgewise Therapeutics (EWTX) Earnings Call Transcripts
- Edgewise Therapeutics Reports $563.3M Cash, Net Loss $40.7M for Q3 2025
EWTX research tape
32 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.